|
|
▲ Hanmi Pharmaceutical Rapid Antigen Diagnosis Kit. |
[에너지경제신문=이나경 기자] Diagnosis kit companies, which continued their high sales streak last year due to Corona special, are expected to maintain rapid growth this year by releasing new products for diagnosing recurrence, side effects, and mutant viruses.
According to the industry on the 18th, the export amount of domestic diagnostic kits again set a record record last month. Last month, the export amount of diagnostic kits announced by the Korea Customs Service was about 340 billion won as of the date of repair (the date when export customs was completed). This was an increase of 941% compared to the same month last year, up 5.4% compared to the previous November. In particular, Seegene, one of the leading domestic diagnostic kit companies, started developing a new coronavirus infection (Corona 19) diagnostic kit from the beginning of the outbreak and responded quickly, and as a result, accounts for about 50% of Korea’s total diagnostic kit export. Currently, Seegene has exported more than 5,500 bit tests to 67 countries through emergency approval from the US Food and Drug Administration (FDA) and European in vitro diagnostic reagent certification (CE-IVD), including Korea’s Ministry of Food and Drug Safety. Recently, it has also obtained permission to change the European in vitro diagnostic reagent certification (CE-IVD) for applying the saliva test method to two types of Corona 19 diagnostic kits. Seegene is confident that this year will continue to grow continuously from last year.
Seegene said, “Unlike in Korea, where the spread of the spread has been somewhat quiet, the virus is not easily detected overseas, such as British, South African, and Japanese mutations, so the demand for diagnostic kits will remain this year.” In addition, by developing various diagnostic reagents for other diseases, sales are expected to increase continuously even in the post-corona era.” In fact, Seegene is active in the market with products that have improved performance from existing corona diagnostic kits and products for various diseases such as △ Influenza A and B flu △ Respiratory Cell Convergence Virus (RSV) A, Type B △ HPV (cervical cancer). Are serving as.
Solgent is targeting the overseas market with a 100% localized Corona 19 diagnostic kit. Solgent has been selling Corona 19 diagnostic kits to more than 60 countries around the world by completing registration in more than 15 countries around the world, including approval for emergency use in Korea as well as approval by the US Food and Drug Administration (FDA) last year. Recently, the company’s diagnostic kit has received attention as it revealed that it can accurately diagnose a mutant virus from the UK. Solgent Co-CEO Yoo Jae-hyung said, “We are developing a diagnostic kit that separates the existing Corona 19 virus and the new variant Corona 19 virus.” “Do it”. Solgent plans to complete the listing process in July as early as March after submitting a request for preliminary examination for listing on the KOSDAQ, going through domestic and overseas company briefing sessions (IR) and demand forecasting in the first half of the year.
Hanmi Pharmaceutical also entered the diagnostic kit business. Hanmi Pharm has developed a rapid antigen diagnosis kit that can check for infection within 30 minutes. This product is an antigen diagnostic test medical device approved for emergency use by the World Health Organization (WHO), and is a diagnostic kit with excellent performance of 90% sensitivity and 96% specificity. Rapid antigen diagnosis kit is a product using an antigen-antibody binding reaction in which a sample collected from the nasal cavity is dropped into the kit and the viral antigen binds to the antibody contained in the kit, and the test result is obtained. Similar. Regarding the background of entering the market, Hanmi Pharm explained, “We are planning to enter the market in view of the fact that the corona spread is still continuing at home and abroad.” In fact, the industry predicts that the demand for diagnostic kits will continue this year, given that Corona is still in progress.
An industry official said, “Even after vaccination, several additional diagnoses are required, and diagnostic kits for recurrence, side effects, and mutant virus diagnosis are still necessary.” As the demand for products for diseases is also increasing, the importance of diagnostic kits will remain unchanged this year.”
Reporter Lee Na-kyung [email protected]